Page 148 - 南京医科大学学报自然科学版

第41卷第6期
·926 · 南 京 医 科 大 学 学 报 2021年6月

bon ion radiation in patients with locoregionally recurrent coregionally advanced nasopharyngeal carcinoma：a big ⁃
nasopharyngeal carcinoma：initial results［J］. Cancer， data，intelligence platform⁃based analysis［J］. BMC Can⁃

2018，124（11）：2427-2437 cer，2018，18（1）：323
［9］ CHAN A T，LEUNG S F，NGAN R K，et al. Overall sur⁃ ［19］ LIN M，YOU R，LIU Y P，et al. Beneficial effects of anti⁃
vival after concurrent cisplatin ⁃ radiotherapy compared EGFR agents，Cetuximab or Nimotuzumab，in combina⁃
with radiotherapy alone in locoregionally advanced naso⁃ tion with concurrent chemoradiotherapy in advanced naso⁃
pharyngeal carcinoma［J］. J Natl Cancer Inst，2005，97 pharyngeal carcinoma［J］. Oral Oncol，2018，80：1-8
（7）：536-539 ［20］ LI Y，CHEN Q Y，TANG L Q，et al. Concurrent chemora⁃
［10］ WU F，WANG R，LU H，et al. Concurrent chemoradiother⁃ diotherapy with or without cetuximab for stage Ⅱ to Ⅳb
apy in locoregionally advanced nasopharyngeal carcino⁃ nasopharyngeal carcinoma：a case⁃control study［J］. BMC
ma：treatment outcomes of a prospective，multicentric clin⁃ Cancer，2017，17（1）：567
ical study［J］. Radiother Oncol，2014，112（1）：106-111 ［21］ LIANG Z G，LIN G X，YE J X，et al. Cetuximab or nimotu⁃
［11］ WU F，WANG R，LU H，et al. Induction chemotherapy fol⁃ zumab versus cisplatin concurrent with radiotherapy for
lowed by concurrent chemoradiotherapy versus concur⁃ local ⁃ regionally advanced nasopharyngeal carcinoma：a
rent chemoradiotherapy alone in locoregionally advanced meta⁃analysis［J］. Asian Pac J Cancer Prev，2018，19（5）：
nasopharyngeal carcinoma：long ⁃ term results of a phase 1397-1404
Ⅲ multicentre randomised controlled trial［J］. Eur J Can⁃ ［22］ SHEN J，SUN C，ZHOU M，et al. Combination treatment
cer，2019，119：87-96 with cetuximab in advanced nasopharyngeal carcinoma
［12］ ZHANG Y，CHEN L，HU G Q，et al. Gemcitabine and cis⁃ patients：a meta⁃analysis［J］. Onco Targets Ther，2019，
platin induction chemotherapy in nasopharyngeal carcino⁃ 12：2477-2494
ma［J］. N Engl J Med，2019，381（12）：1124-1135 ［23］ YUAN C，XU X H，XU L，et al. Cetuximab versus nimotu⁃
［13］ TIAN R，YE H X，ZHANG B G，et al. Use of taxane⁃con⁃ zumab for the treatment of advanced nasopharyngeal car⁃
taining induction chemotherapy in combination with con⁃ cinoma：a network meta⁃analysis［J］. J BUON，2017，22
current chemoradiotherapy in Chinese patients with local⁃ （4）：1004-1010
ly advanced nasopharyngeal carcinoma：a meta ⁃ analysis ［24］ STRAATHOF K C，BOLLARD C M，POPAT U，et al.
［J］. Onco Targets Ther，2015，8：3255-3263 Treatment of nasopharyngeal carcinoma with Epstein⁃Barr
［14］ YAN H，TAO G，WANG J，et al. Which induction chemo⁃ virus⁃specific T lymphocytes［J］. Blood，2005，105（5）：
therapy regimen followed by cisplatin ⁃ based concurrent 1898-1904
chemoradiotherapy is the best choice among PF，TP and ［25］ SMITH C，TSANG J，BEAGLEY L，et al. Effective treat⁃
TPF for locoregionally advanced nasopharyngeal carcino⁃ ment of metastatic forms of Epstein⁃Barr virus⁃associated
ma?［J］. Ann Transl Med，2019，7（5）：104-104 nasopharyngeal carcinoma with a novel adenovirus⁃based
［15］ ZHOU R，ZHU J，CHEN X，et al. The efficacy and safety adoptive immunotherapy［J］. Cancer Res，2012，72（5）：
of docetaxel，cisplatin and fluorouracil（TPF）⁃ based in⁃ 1116-1125
duction chemotherapy followed by concurrent chemoradio⁃ ［26］ CHIA W K，TEO M，WANG W W，et al. Adoptive T⁃cell
therapy for locoregionally advanced nasopharyngeal carci⁃ transfer and chemotherapy in the first ⁃ line treatment of
noma：a meta⁃analysis［J］. Clin Transl Oncol，2020，22 metastatic and/or locally recurrent nasopharyngeal carci⁃
（3）：429-439 noma［J］. Mol Ther，2014，22（1）：132-139
［16］ WANG Q，XU G，XIA Y，et al. Comparison of induction ［27］ ZHAO J J，ZHOU S，CHEN C L，et al. Clinical effect of
chemotherapy plus concurrent chemoradiotherapy and in⁃ adjuvant Cytokine⁃Induced killer cells immunotherapy in
duction chemotherapy plus radiotherapy in locally ad⁃ patients with stage Ⅱ⁃ⅣB nasopharyngeal carcinoma af⁃
vanced nasopharyngeal carcinoma［J］. Oral Oncol，2020， ter chemoradiotherapy：a propensity score analysis［J］. J
111：104925 Cancer，2018，9（22）：4204-4214
［17］ ZHANG L，HUANG Y，HONG S D，et al. Gemcitabine ［28］ 陈 渊，陈仁杰，黄骁辰，等. 潜伏膜蛋白 2A 嵌合抗原
plus cisplatin versus fluorouracil plus cisplatin in recur⁃ 受体⁃T细胞的制备及对NPC细胞杀伤作用的研究［J］.
rent or metastatic nasopharyngeal carcinoma：a multicen⁃ 中华耳鼻咽喉头颈外科杂志，2018，53（12）：925-930
tre，randomised，open ⁃ label，phase 3 trial［J］. Lancet， ［29］ HSU C，LEE S H，EJADI S，et al. Safety and antitumor ac⁃
2016，388（154）：1883-1892 tivity of pembrolizumab in patients with programmed
［18］ PENG H，TANG L L，LIU X，et al. Anti⁃EGFR targeted death ⁃ ligand 1 ⁃ positive nasopharyngeal carcinoma：re⁃
therapy delivered before versus during radiotherapy in lo⁃ （下转第936页）